Suggested remit: To appraise the clinical and cost effectiveness of ublituximab within its marketing authorisation for treating relapsing multiple sclerosis.
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process Cost Comparison Standard
ID number 6350

Project Team

Project lead Jeremy Powell

Email enquiries

External Assessment Group Centre for Reviews and Dissemination and Centre for Health Economics, University of York


Companies sponsors Neuraxpharm UK (ublituximab)
Others Department of Health and Social Care
  NHS England
Patient carer groups Brain and Spine Foundation
  Brain Charity
  Multiple Sclerosis National Therapy Centres
  Multiple Sclerosis Society
  Multiple Sclerosis Trust
  Neurological Alliance
  South Asian Health Foundation
  Specialised Healthcare Alliance
Professional groups Association of British Neurologists
  British Association of Neuroscience Nurses
  British Geriatrics Society
  British Neuropathological Society
  British Society for Blood and Marrow Transplantation and Cellular Therapy
  British Society of Physical and Rehabilitation Medicine
  Chartered Society of Physiotherapy
  Institute of Neurology
  London MS-AHSCT Collaborative Group
  National Neurosciences Advisory Group
  Primary Care and Community Neurology Society
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Occupational Therapists
  Royal College of Pathologists
  Royal College of Physicians
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Therapists in MS
  UK Clinical Pharmacy Association
  UK Multiple Sclerosis Specialist Nurse Association
Associated public health groups Public Health Wales
  UK Health Security Agency
Comparator companies Novartis Pharmaceuticals UK Ltd (ofatumumab)
  Roche Products Limited (ocrelizumab)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health - Northern Ireland
  Healthcare Improvement Scotland
  Health Technology Wales
  Medicines and Healthcare products Regulatory Agency
  Multiple Sclerosis Society Wales
  National Association of Primary Care
  National Pharmacy Association
  Neurological Alliance of Scotland
  NHS Confederation
  Scottish Medicines Consortium
  Wales Neurological Alliance
  Welsh Government
  Welsh Health Specialised Services Committee
Relevant research groups Brain Research UK
  Cochrane Multiple Sclerosis and Rare Diseases of the Central Nervous System Group
  Genomics England
  MRC Clinical Trials Unit
  National Institute for Health Research


Key events during the development of the guidance:

Date Update
27 June 2024 Invitation to participate
11 March 2024 - 10 April 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6350
11 March 2024 In progress. Scoping commenced.
31 January 2023 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual